Last Price$213.6(1.4%)
Market Cap$375.8B
LTM Operating Cash Flow margin
33.4%
5Y avg
39.7%
Drug Manufacturers - General industry
median
27.3%
Stock quality & Intrinsic value
6/10
0.4% undervalued
AbbVie Inc. Operating Cash Flow margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow margin | 37.8% | 31.8% | 35.8% | 34.5% | 33.4% | 17.8% | 33.0% | 27.5% | 35.3% | 41.0% | 40.1% | 38.4% | 40.5% | 43.0% | 42.0% | 33.4% |
Overvalued or undervalued?
Check the intrinsic value for ABBV
and see if it's the right time to invest.
AbbVie Inc. (ABBV) Operating Cash Flow margin comparison analysis
General
LTM Operating Cash Flow margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
AbbVie Inc.ABBV
33.4%
3.7%
(11.4%)
7.6%
Median Peer Set
30.4%
9.8%
11.0%
14.4%
Novo Nordisk A/SNVO
41.7%
24.9%
142.8%
34.8%
Gilead Sciences, Inc.GILD
37.7%
6.0%
(91.6%)
1.7%
Novartis AGNVS
34.5%
10.8%
(16.5%)
23.1%
Amgen Inc.AMGN
34.4%
18.6%
(39.8%)
12.2%
Merck & Co., Inc.MRK
33.5%
6.7%
4,714.3%
26.7%
Johnson & JohnsonJNJ
27.3%
4.3%
(57.9%)
15.8%
AstraZeneca PLCAZN
21.9%
18.0%
18.9%
13.0%
Pfizer Inc.PFE
20.0%
8.8%
273.7%
12.6%
Eli Lilly and CompanyLLY
19.6%
32.0%
102.4%
23.5%
SanofiSNY
3.2%
(3.8%)
3.1%
12.6%
ABBV key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 14,214.2 0.0% | 15,638.0 10.0% | 17,444.0 11.5% | 18,380.0 5.4% | 18,790.0 2.2% | 19,960.0 6.2% | 22,859.0 14.5% | 25,638.0 12.2% | 28,216.0 10.1% | 32,753.0 16.1% | 33,266.0 1.6% | 45,804.0 37.7% | 56,197.0 22.7% | 58,054.0 3.3% | 54,318.0 (6.4%) | 56,334.0 3.7% |
| Cost of Goods Sold (COGS) | 4,056.4 | 4,293.0 | 4,639.4 | 4,508.0 | 4,581.0 | 4,426.0 | 4,500.0 | 5,833.0 | 7,040.0 | 7,718.0 | 7,439.0 | 15,387.0 | 17,446.0 | 17,414.0 | 20,415.0 | 16,904.0 |
% margin | 10,157.8 71.5% | 11,345.0 72.5% | 12,804.6 73.4% | 13,872.0 75.5% | 14,209.0 75.6% | 15,534.0 77.8% | 18,359.0 80.3% | 19,805.0 77.2% | 21,176.0 75.0% | 25,035.0 76.4% | 25,827.0 77.6% | 30,417.0 66.4% | 38,751.0 69.0% | 40,640.0 70.0% | 33,903.0 62.4% | 39,430.0 70.0% |
| Operating Expenses | 5,056.0 | 6,315.0 | 8,511.3 | 7,767.0 | 8,207.0 | 11,771.0 | 10,672.0 | 10,221.0 | 11,257.0 | 18,228.0 | 12,459.0 | 17,856.0 | 19,865.0 | 21,826.0 | 21,146.0 | 30,293.0 |
| Research & Development Expenses (R&D) | 1,707.4 | 2,495.0 | 2,617.5 | 2,778.0 | 2,855.0 | 3,297.0 | 4,285.0 | 4,366.0 | 4,982.0 | 10,329.0 | 6,407.0 | 6,557.0 | 7,084.0 | 6,510.0 | 8,453.0 | 12,791.0 |
| Selling, General & Administrative Expenses (SG&A) | 3,348.6 | 3,820.0 | 5,893.8 | 4,989.0 | 5,352.0 | 7,724.0 | 6,387.0 | 5,855.0 | 6,275.0 | 7,399.0 | 6,942.0 | 11,299.0 | 12,349.0 | 15,260.0 | 12,872.0 | 14,752.0 |
% margin | 4,931.8 34.7% | 4,717.0 30.2% | 3,620.7 20.8% | 6,622.0 36.0% | 5,664.0 30.1% | 3,411.0 17.1% | 7,537.0 33.0% | 9,340.0 36.4% | 9,545.0 33.8% | 6,383.0 19.5% | 12,983.0 39.0% | 11,363.0 24.8% | 17,924.0 31.9% | 18,117.0 31.2% | 12,757.0 23.5% | 9,137.0 16.2% |
| Interest Income | 0.0 | 28.0 | 20.0 | 20.0 | 21.0 | 38.0 | 33.0 | 82.0 | 146.0 | 204.0 | 275.0 | 174.0 | 39.0 | 186.0 | 540.0 | 648.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 104.0 | 299.0 | 429.0 | 719.0 | 1,047.0 | 1,150.0 | 1,348.0 | 1,784.0 | 2,454.0 | 2,423.0 | 2,230.0 | 2,224.0 | 2,808.0 |
| Pre-tax Income | 5,950.3 | 4,836.0 | 3,668.5 | 5,725.0 | 5,332.0 | 2,369.0 | 6,645.0 | 7,884.0 | 7,727.0 | 5,197.0 | 8,426.0 | 3,398.0 | 12,989.0 | 13,477.0 | 6,250.0 | 3,716.0 |
% effective tax rate | 1,313.8 22.1% | 658.0 13.6% | 235.4 6.4% | 450.0 7.9% | 1,204.0 22.6% | 595.0 25.1% | 1,501.0 22.6% | 1,931.0 24.5% | 2,418.0 31.3% | 490.0 9.4% | 544.0 6.5% | 1,224.0 36.0% | 1,440.0 11.1% | 1,632.0 12.1% | 1,377.0 22.0% | (570.0) (15.3%) |
% margin | 4,636.5 32.6% | 4,178.0 26.7% | 3,433.1 19.7% | 5,275.0 28.7% | 4,128.0 22.0% | 1,774.0 8.9% | 5,144.0 22.5% | 5,953.0 23.2% | 5,309.0 18.8% | 5,687.0 17.4% | 7,882.0 23.7% | 4,616.0 10.1% | 11,542.0 20.5% | 11,836.0 20.4% | 4,863.0 9.0% | 4,278.0 7.6% |
| EPS | 2.87 | 2.59 | 2.12 | 3.35 | 2.58 | 1.11 | 3.15 | 3.65 | 3.31 | 3.69 | 5.30 | 2.73 | 6.48 | 6.65 | 2.73 | 2.42 |
| Diluted EPS | 2.85 | 2.57 | 2.11 | 3.35 | 2.56 | 1.10 | 3.13 | 3.63 | 3.30 | 3.68 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.41 |
% margin | 6,647.8 46.8% | 6,020.0 38.5% | 4,940.7 28.3% | 6,979.0 38.0% | 6,914.0 36.8% | 6,286.0 31.5% | 9,692.0 42.4% | 10,812.0 42.2% | 11,774.0 41.7% | 13,688.0 41.8% | 16,264.0 48.9% | 21,148.0 46.2% | 28,280.0 50.3% | 31,424.0 54.1% | 17,308.0 31.9% | 14,910.0 26.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is AbbVie Inc.'s Operating Cash Flow margin?
As of today, Microsoft Corp's last 12-month Operating Cash Flow margin is 33.4%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Operating Cash Flow margin for AbbVie Inc. have been 39.8% over the past three years, and 41.7% over the past five years.
2) Is AbbVie Inc.'s Operating Cash Flow margin Good?
As of today, AbbVie Inc.'s Operating Cash Flow margin is 33.4%, which is higher than industry median of 27.3%. It indicates that AbbVie Inc.'s Operating Cash Flow margin is Good.